SCHEMBL10213963

SCHEMBL10213963

Nc1n[nH]c2ccc(-c3cccnc3)cc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 5/20 0.69
DYRK1A Q13627 12/20 0.59
CLK3 P49761 4/20 0.59
CLK2 P49760 4/20 0.59
WNT1 P04628 4/20 0.57
MAP2K4 P45985 1/20 0.56
CDK7 P50613 2/20 0.55
CHEK1 O14757 1/20 0.55
AURKA O14965 1/20 0.55
DAPK3 O43293 1/20 0.55
PRKD3 O94806 1/20 0.55
MAP4K4 O95819 1/20 0.55
PAK4 O96013 1/20 0.55
ABL1 P00519 1/20 0.55
LCK P06239 1/20 0.55
FYN P06241 1/20 0.55
CSF1R P07333 1/20 0.55
RET P07949 1/20 0.55
IGF1R P08069 1/20 0.55
MET P08581 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30588952 1.00 JAK2 (0.69) JAK2DYRK1ACLK3CLK2WNT1
SCHEMBL6492377 0.88 JAK2 (0.69) JAK2DYRK1ACLK2CDK7CHEK1
SCHEMBL29942349 0.84 MAP2K4 (0.64) JAK2DYRK1ACLK3CLK2WNT1
SCHEMBL5514698 0.84 MKNK1 (0.72) JAK2DYRK1ACLK3CLK2WNT1
SCHEMBL17096938 0.83 DYRK1A (0.67) DYRK1ACLK3CLK2WNT1
SCHEMBL10213929 0.83 JAK2 (0.81) JAK2DYRK1ACLK2DAPK3PRKD3
SCHEMBL3359889 0.82 JAK2 (1.00) JAK2DYRK1ACLK2AURKADAPK3
SCHEMBL12907246 0.82 JAK2 (1.00) JAK2DYRK1ACLK2AURKADAPK3
SCHEMBL31690865 0.80 JAK2 (1.00) JAK2DYRK1ACLK2CDK7DAPK3
SCHEMBL31240306 0.79 DYRK1A (0.71) DYRK1ACLK3CLK2WNT1TBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230272401-A1 COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF Genetic Intelligence, Inc 2023-08-31 US disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 JAK2 1822/4885DYRK1A 3722/4885CLK3 1887/4885
US-20230272401-A1 COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF TARDBP, FUS, RBM17 JAK2 4885/4885DYRK1A 4611/4885CLK3 3655/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 JAK2 1822/4885DYRK1A 3722/4885CLK3 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.